Medication Therapy Management With Pharmacogenetic Testing
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/8/2014 |
| Start Date: | November 2013 |
| Contact: | Jivan Moaddeb, PharmD |
| Email: | jivan.moaddeb@duke.edu |
| Phone: | 919 681 3499 |
Assessing Feasibility and Utility of Enhancing Medication Therapy Management With Pharmacist-Delivered Pharmacogenetic Testing
This study aims to investigate the benefit and feasibility of providing pharmacogenetic
(PGx) testing as part of a standard medication therapy management (MTM) session for patients
taking multiple medications, a high-risk population for adverse drug reactions and
non-response. Research participants will attend two MTM sessions and undergo PGx testing to
inform the MTM plan. Participants will also complete 2 surveys pre and post-MTM/PGx testing.
Data analysis will assess the impact of MTM/PGx testing on recommendations for drug dosing,
clinical outcomes, patient satisfaction, and feasibility of service delivery. Safety issues
are minimal with the primary risks being associated with loss of confidentiality, typical
discomfort associated with acquiring blood samples, and genetic discrimination.
(PGx) testing as part of a standard medication therapy management (MTM) session for patients
taking multiple medications, a high-risk population for adverse drug reactions and
non-response. Research participants will attend two MTM sessions and undergo PGx testing to
inform the MTM plan. Participants will also complete 2 surveys pre and post-MTM/PGx testing.
Data analysis will assess the impact of MTM/PGx testing on recommendations for drug dosing,
clinical outcomes, patient satisfaction, and feasibility of service delivery. Safety issues
are minimal with the primary risks being associated with loss of confidentiality, typical
discomfort associated with acquiring blood samples, and genetic discrimination.
Inclusion Criteria:
- currently prescribed 3 medications, one of which must be simvastatin or clopidogrel
- 18 years of age or older
- English speaking
- patients of Mahesh Patel or William Kraus at Duke Southpoint Clinic
Exclusion Criteria:
- if patient has ever had MTM or PGx
We found this trial at
1
site
Click here to add this to my saved trials
